Breaking News, Trials & Filings

Lucentis Meets Phase III Endpoint in DME

Genentech’s Phase III study evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

@font-face { font-family: “Cambria”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }div.Section1 { page: Section1; } @font-face { font-family: “Cambria”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters